Corporate venture capital arm of Japan’s Taiho Pharmaceutical investing in early-stage biotechnology companies relevant to oncology, allergy, immunology and urology. It backs therapeutic platforms and drug developers through equity investments, company creation, spin-outs and option-based investments. Its current website reports USD400 million under management; this is aggregate managed capital rather than a newly verified fund close.